Literature DB >> 7495760

Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme.

J M Buchanan1, L A Vogel, V H Van Cleave, D W Metzger.   

Abstract

Protein antigens elicit humoral responses in mice that consist predominantly of IgG1 antibodies. We have now investigated the ability of IL-12, a cytokine reported to augment IgG2a anti-hapten responses through activation of Th1 cells, to alter antibody responses to hen eggwhite lysozyme (HEL). The normal response of BALB/c mice to HEL is highly restricted to IgG1 expression and therefore provides an excellent system for determining effects of cytokines on expression of other isotypes. Seven days after immunization, IL-12 treated mice demonstrated greatly elevated HEL-specific IgG2a antibody levels and suppressed IgG1 production, while PBS-treated control mice showed a typical IgG1-restricted response. On day 28, IL-12-treated mice showed heightened serum antibody levels of both isotypes. Delaying cytokine treatment until after the typical IgG1 anti-HEL response had already been established also led to significant elevation of serum IgG2a antibody levels. These effects correlated with increased IFN-gamma production; however, administration of IL-12 plus anti-IFN-gamma had little influence on IgG2a enhancement, although it did relieve the early IgG1 suppression. Furthermore, the differential effects of Il-12 on isotype expression did not correlate with time; in fact, IgG2a enhancement correlated with loss of IgG1 suppression. Our findings indicate that (i) IL-12 reproducibly induces large amounts of IgG2a HEL-specific antibodies in vivo; (ii) it can alter isotype profiles of both primary and secondary responses; and (iii) its effects on humoral immunity are not completely explained by induction of Th1 cell derived IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495760     DOI: 10.1093/intimm/7.9.1519

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

1.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

Authors:  B P Arulanandam; J M Lynch; D E Briles; S Hollingshead; D W Metzger
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 4.  Interleukin-12 as an adjuvant for induction of protective antibody responses.

Authors:  Dennis W Metzger
Journal:  Cytokine       Date:  2010-07-22       Impact factor: 3.861

5.  Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses.

Authors:  M Marinaro; P N Boyaka; F D Finkelman; H Kiyono; R J Jackson; E Jirillo; J R McGhee
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

6.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

7.  Tailored vaccines targeting the elderly using whole inactivated influenza vaccines bearing cytokine immunomodulators.

Authors:  Tila Khan; Connie L Heffron; Kevin P High; Paul C Roberts
Journal:  J Interferon Cytokine Res       Date:  2013-10-08       Impact factor: 2.607

8.  Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.

Authors:  Toshio Iinuma; Sadamu Homma; Tetsuo Noda; Donald Kufe; Tsuneya Ohno; Gotaro Toda
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.

Authors:  Joshua M Klonoski; Heather R Hurtig; Brian A Juber; Margaret J Schuneman; Thomas E Bickett; Joshua M Svendsen; Brandon Burum; Thomas A Penfound; Grigoriy Sereda; James B Dale; Michael S Chaussee; Victor C Huber
Journal:  Vaccine       Date:  2014-07-29       Impact factor: 3.641

10.  Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation.

Authors:  K M Toellner; A Gulbranson-Judge; D R Taylor; D M Sze; I C MacLennan
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.